🔗 Share this article

While the United States undertakes unprecedented changes to its vaccination guidelines, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines in the pandemic and has focused upon potential fatalities after Covid vaccination in her recent time at the FDA.

Scheduled Overhauls to Childhood Vaccine Program

Public health authorities were set to reveal major revisions to the childhood immunization program earlier this month, bringing the US with Denmark’s national calendar, it is understood – a significant shift that would place the US at odds with much of the global community with little proof for public health gain. The planned update has been postponed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to address the audience at the gathering. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to run the office this year.

Consolidating Power at the Agency

This interim role could signify a strengthened alliance between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

Høeg has repeatedly called for ending certain childhood vaccine recommendations in the US in order to be more similar to Denmark's approach, a society with nationalized medicine and a population about the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccination policy – traditionally the purview of Dr. Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Dr. Høeg has no obvious experience in pharmaceutical research, approval processes or management, which has been typical for previous leaders of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and CBER since March.

“She appears not to have the requisite experience” for leading the CDER, said Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a major agency. She lacks background in industry regulation.”

Former commissioners of CBER would “understand laws and regulations and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who led CBER have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner emphasized.

“The public just pays attention on the novel medication approvals, but the generic program approves thousands of generic drugs. There’s a biosimilars program, OTC medication office and so forth, and every single one need to be looked after,” she noted. “The thing you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the job, which manages over 5,000 personnel. “It’s a huge management job, if you execute it properly,” the former official said.

Official Statement and Contentious Programs

Regarding concerns about Dr. Høeg's fitness for the role and whether this appointment indicates greater collaboration among FDA leaders on vaccines, a representative said that the “questions are based on inaccurate premises”.

“This background aligns with the responsibilities of her role,” the representative stated, noting the period Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the agency head's controversial expedited review system, a disputed rapid medication authorization process that reportedly concerned her predecessors. “By what process are these therapies being chosen for this expedited pathway? Who is making the decisions?” Howard questioned. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he said, “the agency appears to be shifting towards laxer regulations of most medications, except for vaccines.”

Public History on Vaccines

With immunizations, Dr. Høeg has a more documented, if problematic, past, some experts observe. She authored a research paper using unconfirmed crowd-sourced reports to estimate the rate of heart inflammation following Covid vaccination. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the incoming federal leadership encompassed altering regulations for new vaccines and discontinuing “non-essential” immunizations, she said post-election on a online show. At the FDA, Dr. Høeg has according to sources suggested excluding adolescent males from receiving COVID-19 vaccines.

“She is an all-around dogmatist who commences with her preconceived notions and reverse-engineers to accommodate the science in a extremely deceptive, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|